{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:10:06Z","timestamp":1782025806516,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NHLBI 1K12HL138049\u201301"],"award-info":[{"award-number":["NHLBI 1K12HL138049\u201301"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.cct.2023.107082","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T13:03:37Z","timestamp":1673269417000},"page":"107082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Patient- reported reasons for non-participation in a COVID-19 therapeutics clinical trial: Findings from a multi-center investigation"],"prefix":"10.1016","volume":"126","author":[{"given":"Samira Reyes","family":"Dassum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Visnaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Monach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Leatherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Westyn","family":"Branch-Elliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2023.107082_bb0005","author":"COVID-19 Map"},{"issue":"8","key":"10.1016\/j.cct.2023.107082_bb0010","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.cct.2023.107082_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263591","article-title":"Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. De Socio GV, ed","volume":"17","author":"Branch-Elliman","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.cct.2023.107082_bb0020","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/d41573-021-00037-3","article-title":"Trends in COVID-19 therapeutic clinical trials","volume":"20","author":"Bugin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.cct.2023.107082_bb0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/cts.12019","article-title":"Public participation in, and awareness about, medical research opportunities in the era of clinical and translational research: awareness about medical research in the era of clinical and translational research","volume":"6","author":"Davis","year":"2013","journal-title":"Clin Transl Sci."},{"issue":"44","key":"10.1016\/j.cct.2023.107082_bb0030","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.1016\/j.vaccine.2019.09.048","article-title":"Barriers and motivations for participation in preventive vaccine clinical trials: experience of 5 clinical research sites","volume":"37","author":"Detoc","year":"2019","journal-title":"Vaccine."},{"key":"10.1016\/j.cct.2023.107082_bb0035","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jclinepi.2017.05.001","article-title":"Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands","volume":"88","author":"van den Bogert","year":"2017","journal-title":"J. Clin. Epidemiol."},{"issue":"24","key":"10.1016\/j.cct.2023.107082_bb0040","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1002\/cncr.29669","article-title":"Case-linked analysis of clinical trial enrollment among adolescents and young adults at a National Cancer Institute-designated comprehensive cancer center: clinical trial enrollment among AYAs","volume":"121","author":"Collins","year":"2015","journal-title":"Cancer."},{"issue":"3","key":"10.1016\/j.cct.2023.107082_bb0045","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1353\/hpu.0.0323","article-title":"More than Tuskegee: understanding mistrust about research participation","volume":"21","author":"Scharff","year":"2010","journal-title":"J. Health Care Poor Underserved"},{"issue":"4","key":"10.1016\/j.cct.2023.107082_bb0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/NNR.0000000000000513","article-title":"Predictors of participation in clinical research","volume":"70","author":"Scanlon","year":"2021","journal-title":"Nurs. Res."},{"issue":"4","key":"10.1016\/j.cct.2023.107082_bb0055","first-page":"290","article-title":"Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities: Cancer statistics for African Americans, 2016","volume":"66","author":"DeSantis","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cct.2023.107082_bb0060","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp Clin Trials Commun."},{"issue":"2\u20133","key":"10.1016\/j.cct.2023.107082_bb0065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1017\/cts.2019.386","article-title":"Designing for accelerated translation (DART) of emerging innovations in health","volume":"3","author":"Ramsey","year":"2019","journal-title":"J Clin Transl Sci."},{"issue":"1","key":"10.1016\/j.cct.2023.107082_bb0070","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1186\/s13063-020-04711-6","article-title":"It is unprecedented: trial management during the COVID-19 pandemic and beyond","volume":"21","author":"Mitchell","year":"2020","journal-title":"Trials."},{"key":"10.1016\/j.cct.2023.107082_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100804","article-title":"Implementation of documented and written informed consent for clinical trials of communicable diseases: lessons learned, barriers, solutions, future directions identified during the conduct of a COVID-19 clinical trial","volume":"23","author":"Woods","year":"2021","journal-title":"Contemp Clin Trials Commun."},{"key":"10.1016\/j.cct.2023.107082_bb0080","series-title":"The National Institutes of Health COVID-19 Treatment Guidelines Panel Provides Recommendations for Dexamethasone in Patients with COVID-19","year":"2020"},{"key":"10.1016\/j.cct.2023.107082_bb0085","author":"Coronavirus Disease 2019 (COVID-19 Treatment Guidelines"},{"issue":"9","key":"10.1016\/j.cct.2023.107082_bb0090","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual. Health Res."},{"key":"10.1016\/j.cct.2023.107082_bb0095","series-title":"Factors Associated with The Speed and Scope of Diffusion of COVID-19 Therapeutics in a Nationwide Healthcare Setting: A Mixed Methods Investigation","author":"La","year":"2022"},{"issue":"9","key":"10.1016\/j.cct.2023.107082_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-048534","article-title":"Reconsidering \u2018minimal risk\u2019 to expand the repertoire of trials with waiver of informed consent for research","volume":"11","author":"Monach","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.cct.2023.107082_bb0105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/EDBK_243729","article-title":"Overcoming barriers to clinical trial enrollment","volume":"39","author":"Nipp","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"10.1016\/j.cct.2023.107082_bb0110","series-title":"Clinical Trials in Vulnerable Populations","article-title":"Access to clinical trials closer to home using tele-health","author":"Sabesan","year":"2018"},{"issue":"1","key":"10.1016\/j.cct.2023.107082_bb0115","first-page":"78","article-title":"Older adult participation in cancer clinical trials: a systematic review of barriers and interventions","volume":"71","author":"Sedrak","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.cct.2023.107082_bb0120","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/cts.13211","article-title":"Chasing the storm: recruiting non-hospitalized patients for a multi-site randomized controlled trial in the United States during the COVID-19 pandemic","volume":"15","author":"Hu","year":"2022","journal-title":"Clin Transl Sci."},{"key":"10.1016\/j.cct.2023.107082_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.608959","article-title":"Factors influencing participation in COVID-19 clinical trials: A Multi-National Study","volume":"8","author":"Abdelhafiz","year":"2021","journal-title":"Front Med."},{"issue":"2","key":"10.1016\/j.cct.2023.107082_bb0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3747\/co.25.3857","article-title":"Barriers to participation in clinical trials: a physician survey","volume":"25","author":"Mahmud","year":"2018","journal-title":"Curr. Oncol."},{"issue":"9","key":"10.1016\/j.cct.2023.107082_bb0135","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1634\/theoncologist.2011-0384","article-title":"A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast Cancer clinical trials (SWOG S0316)","volume":"17","author":"Javid","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.cct.2023.107082_bb0140","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.12688\/f1000research.25842.2","article-title":"Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial","volume":"9","author":"Knowlson","year":"2020","journal-title":"F1000Research."},{"issue":"21","key":"10.1016\/j.cct.2023.107082_bb0150","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative effectiveness of aspirin dosing in cardiovascular disease","volume":"384","author":"Jones","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.cct.2023.107082_bb0155","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1056\/NEJMe2106430","article-title":"Pragmatic trials \u2014 need for ADAPTABLE design","volume":"384","author":"Baigent","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cct.2023.107082_bb0160","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ygyno.2020.03.002","article-title":"Minority participation in phase 1 gynecologic oncology clinical trials: three decades of inequity","volume":"157","author":"Awad","year":"2020","journal-title":"Gynecol. Oncol."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714423000058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714423000058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:58:40Z","timestamp":1761555520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714423000058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":31,"alternative-id":["S1551714423000058"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2023.107082","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient- reported reasons for non-participation in a COVID-19 therapeutics clinical trial: Findings from a multi-center investigation","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2023.107082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107082"}}